Reverse genetics systems as tools for the development of novel therapies against filoviruses

Expert Review of Anti-Infective Therapy

Volumn 12, Issue 10, 2014, Pages 1253-1263

  Hoenen, Thomas ^a   Feldmann, Heinz ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Transcription and replication competent particle system

Indexed keywords

ANTIVIRUS AGENT; PROTEIN VP30; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ANTIVIRAL ACTIVITY; DRUG MECHANISM; DRUG SCREENING; DRUG TARGETING; EBOLA VIRUS; FILOVIRUS; FULL LENGTH CLONE SYSTEM; GENE EXPRESSION; GENE REPLICATION; HIGH THROUGHPUT SCREENING; LIFE CYCLE STAGE; MINIGENOME SYSTEM; MOLECULAR GENETICS; NONHUMAN; PROCESS DEVELOPMENT; REPORTER GENE; REVERSE GENETICS; REVIEW; TRANSCRIPTION AND REPLICATION COMPETENT VIRUS LIKE PARTICLE SYSTEM; VIRUS CELL INTERACTION; VIRUS RECOMBINANT; DRUG DEVELOPMENT; DRUG EFFECTS; EBOLAVIRUS; FILOVIRIDAE; FILOVIRIDAE INFECTIONS; GENETICS; HUMAN; MICROBIAL SENSITIVITY TEST; PHYSIOLOGY; PROCEDURES; THEORETICAL MODEL; VIRUS GENOME; VIRUS REPLICATION;

ANTIVIRAL AGENTS; DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; EBOLAVIRUS; FILOVIRIDAE; FILOVIRIDAE INFECTIONS; GENOME, VIRAL; HUMANS; MICROBIAL SENSITIVITY TESTS; MODELS, THEORETICAL; REVERSE GENETICS; VIRUS REPLICATION;

EID: 84907049388     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/14787210.2014.948848     Document Type: Review

References (60)

1. Sanchez A, Geisbert TW, Feldmann H. Filoviridae: Marburg and Ebola Viruses. In: Fields BN, Knipe DM, Howley PM, editors. Fields virology. 6th edition. Lippincott Williams & Wilkins; Philadelphia, USA: 2013
2. Baize S, Pannetier D, Oestereich L, et al. Emergence of Zaire Ebola virus disease in Guinea-preliminary report. N Engl J Med 2014. [Epub ahead of print]
3. Kortepeter MG, Bausch DG, Bray M. Basic clinical and laboratory features of filoviral hemorrhagic fever. J Infect Dis 2011; 204(Suppl 3):S810-16
4. Hoenen T, Groseth A, Falzarano D, Feldmann H. Ebola virus: unravelling pathogenesis to combat a deadly disease. Trends Mol Med 2006;12(5):206-15
5. Roddy P, Colebunders R, Jeffs B, et al. Filovirus hemorrhagic fever outbreak case management: a review of current and future treatment options. J Infect Dis 2011; 204(Suppl 3):S791-5
6. Muhlberger E, Lötfering B, Klenk HD, Becker S. Three of the four nucleocapsid proteins of Marburg virus, NP, VP35, and L, are sufficient to mediate replication and transcription of Marburg virus-specific monocistronic minigenomes. J Virol 1998; 72(11):8756-64
7. Muhlberger E, Weik M, Volchkov VE, et al. Comparison of the transcription and replication strategies of Marburg virus and Ebola virus by using artificial replication systems. J Virol 1999;73(3):2333-42
8. Bharat TA, Riches JD, Kolesnikova L, et al. Cryo-electron tomography of Marburg virus particles and their morphogenesis within infected cells. PLoS Biol 2011;9(11): e1001196
9. Beniac DR, Melito PL, Devarennes SL, et al. The organisation of Ebola virus reveals a capacity for extensive, modular polyploidy. PLoS One 2012;7(1):e29608
10. Aleksandrowicz P, Marzi A, Biedenkopf N, et al. Ebola virus enters host cells by macropinocytosis and clathrin-mediated endocytosis. J Infect Dis 2011; 204(Suppl 3):S957-67
11. Nanbo A, Imai M, Watanabe S, et al. Ebolavirus is internalized into host cells via macropinocytosis in a viral glycoprotein-dependent manner. PLoS Pathog 2010;6(9):e1001121
12. Miller EH, Chandran K. Filovirus entry into cells-new insights. Curr Opin Virol 2012;2(2):206-14
13. Hoenen T, Shabman RS, Groseth A, et al. Inclusion bodies are a site of ebolavirus replication. J Virol 2012;86(21):11779-88
14. Nanbo A, Watanabe S, Halfmann P, Kawaoka Y. The spatio-temporal distribution dynamics of Ebola virus proteins and RNA in infected cells. Sci Rep 2013;3:1206
15. Harty RN, Brown ME, Wang G, et al. A PPxY motif within the VP40 protein of Ebola virus interacts physically and functionally with a ubiquitin ligase: implications for filovirus budding. Proc Natl Acad Sci USA 2000;97(25):13871-6
16. Timmins J, Scianimanico S, Schoehn G, Weissenhorn W. Vesicular release of ebola virus matrix protein VP40. Virology 2001; 283(1):1-6
17. Jasenosky LD, Neumann G, Lukashevich I, Kawaoka Y. Ebola virus VP40-induced particle formation and association with the lipid bilayer. J Virol 2001;75(11):5205-14
18. Falzarano D, Feldmann H. Possible leap ahead in filovirus therapeutics. Cell Res 2014;24(6):647-8
19. Hoenen T, Groseth A, Feldmann H. Current ebola vaccines. Expert Opin Biol Ther 2012;12(7):859-72
20. Hoenen T, Groseth A, de Kok-Mercado F, et al. Minigenomes, transcription and replication competent virus-like particles and beyond: reverse genetics systems for filoviruses and other negative stranded hemorrhagic fever viruses. Antiviral Res 2011;91(2):195-208
21. Neumann G, Feldmann H, Watanabe S, et al. Reverse genetics demonstrates that proteolytic processing of the Ebola virus glycoprotein is not essential for replication in cell culture. J Virol 2002;76(1):406-10
22. Volchkov VE, Volchkova VA, Muhlberger E, et al. Recovery of infectious Ebola virus from complementary DNA: RNA editing of the GP gene and viral cytotoxicity. Science 2001;291(5510): 1965-9
23. Watt A, Moukambi F, Banadyga L, et al. A novel lifecycle modeling system for Ebola virus shows a genome length-dependent role of VP24 on virus infectivity. J Virol 2014. [Epub ahead of print]
24. Hoenen T, Groseth A, Kolesnikova L, et al. Infection of naive target cells with virus-like particles: implications for the function of ebola virus VP24. J Virol 2006;80(14): 7260-4
25. Watanabe S, Watanabe T, Noda T, et al. Production of novel ebola virus-like particles from cDNAs: an alternative to ebola virus generation by reverse genetics. J Virol 2004; 78(2):999-1005
26. Wenigenrath J, Kolesnikova L, Hoenen T, et al. Establishment and application of an infectious virus-like particle system for Marburg virus. J Gen Virol 2010;91(Pt 5): 1325-34
27. Shabman RS, Hoenen T, Groseth A, et al. An upstream open reading frame modulates ebola virus polymerase translation and virus replication. PLoS Pathog 2013;9(1): e1003147
28. Neumann G, Ebihara H, Takada A, et al. Ebola virus VP40 late domains are not essential for viral replication in cell culture. J Virol 2005;79(16):10300-7
29. Groseth A, Feldmann H, Theriault S, et al. RNA polymerase I-driven minigenome system for Ebola viruses. J Virol 2005; 79(7):4425-33
30. Hoenen T, Jung S, Herwig A, et al. Both matrix proteins of Ebola virus contribute to the regulation of viral genome replication and transcription. Virology 2010;403(1): 56-66
31. Spiegelberg L, Wahl-Jensen V, Kolesnikova L, et al. Genus-specific recruitment of filovirus ribonucleoprotein complexes into budding particles. J Gen Virol 2011;92(Pt 12):2900-5
32. Halfmann P, Kim JH, Ebihara H, et al. Generation of biologically contained Ebola viruses. Proc Natl Acad Sci USA 2008; 105(4):1129-33
33. Takahashi K, Halfmann P, Oyama M, et al. DNA topoisomerase 1 facilitates the transcription and replication of the Ebola virus genome. J Virol 2013;87(16):8862-9
34. Halfmann P, Ebihara H, Marzi A, et al. Replication-deficient ebolavirus as a vaccine candidate. J Virol 2009;83(8):3810-15
35. Falzarano D, Groseth A, Hoenen T. Development and application of reporter-expressing mononegaviruses: Current challenges and perspectives. Antiviral Res 2014;103:78-87
36. Towner JS, Paragas J, Dover JE, et al. Generation of eGFP expressing recombinant Zaire ebolavirus for analysis of early pathogenesis events and high-throughput antiviral drug screening. Virology 2005; 332(1):20-7
37. Ebihara H, Theriault S, Neumann G, et al. In vitro and in vivo characterization of recombinant Ebola viruses expressing enhanced green fluorescent protein. J Infect Dis 2007;196(Suppl 2):S313-22
38. Schmidt KM, Schumann M, Olejnik J, et al. Recombinant Marburg virus expressing EGFP allows rapid screening of virus growth and real-time visualization of virus spread. J Infect Dis 2011; 204(Suppl 3)):S861-70
39. Hoenen T, Groseth A, Callison J, et al. A novel Ebola virus expressing luciferase allows for rapid and quantitative testing of antivirals. Antiviral Res 2013;99(3):207-13
40. Uebelhoer LS, Albariño CG, McMullan LK, et al. High-throughput, luciferase-based reverse genetics systems for identifying inhibitors of Marburg and Ebola viruses. Antiviral Res 2014;106:86-94
41. Pegoraro G, Bavari S, Panchal RG. Shedding light on filovirus infection with high-content imaging. Viruses 2012;4(8): 1354-71
42. Panchal RG, Kota KP, Spurgers KB, et al. Development of high-content imaging assays for lethal viral pathogens. J Biomol Screen 2010;15(7):755-65
43. Johansen LM, Brannan JM, Delos SE, et al. FDA-approved selective estrogen receptor modulators inhibit Ebola virus infection. Sci Transl Med 2013;5(190):190ra79
44. Groseth A, Hoenen T, Alimonti JB, et al. In vitro evaluation of antisense RNA efficacy against filovirus infection, by use of reverse genetics. J Infect Dis 2007; 196(Suppl 2):S382-9
45. Jasenosky LD, Neumann G, Kawaoka Y. Minigenome-based reporter system suitable for high-throughput screening of compounds able to inhibit Ebolavirus replication and/or transcription. Antimicrob Agents Chemother 2010;54(7):3007-10
46. Zhang JH, Chung TD, Oldenburg KR. A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen 1999;4(2):67-73
47. Geisbert TW, Bausch DG, Feldmann H. Prospects for immunisation against Marburg and Ebola viruses. Rev Med Virol 2010; 20(6):344-57
48. Filone CM, Hodges EN, Honeyman B, et al. Identification of a broad-spectrum inhibitor of viral RNA synthesis: validation of a prototype virus-based approach. Chem Biol 2013;20(3):424-33
49. Kolokoltsov AA, Adhikary S, Garver J, et al. Inhibition of Lassa virus and Ebola virus infection in host cells treated with the kinase inhibitors genistein and tyrphostin. Arch Virol 2012;157(1):121-7
50. Kinch MS, Yunus AS, Lear C, et al. FGI-104: a broad-spectrum small molecule inhibitor of viral infection. Am J Transl Res 2009;1(1):87-98
51. Warren TK, Wells J, Panchal RG, et al. Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430. Nature 2014;508(7496):402-5
52. Brown CS, Lee MS, Leung DW, et al. In silico derived small molecules bind the filovirus VP35 protein and inhibit its polymerase cofactor activity. J Mol Biol 2014;426(10):2045-58
53. Trunschke M, Conrad D, Enterlein S, et al. The L-VP35 and L-L interaction domains reside in the amino terminus of the Ebola virus L protein and are potential targets for antivirals. Virology 2013;441(2):135-45
54. Binning JM, Wang T, Luthra P, et al. Development of RNA aptamers targeting Ebola virus VP35. Biochemistry 2013; 52(47):8406-19
55. Hill-Batorski L, Halfmann P, Neumann G, Kawaoka Y. The cytoprotective enzyme heme oxygenase-1 suppresses Ebola virus replication. J Virol 2013;87(24):13795-802
56. Tigabu B, Rasmussen L, White EL, et al. A BSL-4 high-throughput screen identifies sulfonamide inhibitors of Nipah virus. Assay Drug Dev Technol 2014;12(3):155-61
57. Panchal RG, Reid SP, Tran JP, et al. Identification of an antioxidant small-molecule with broad-spectrum antiviral activity. Antiviral Res 2012;93(1): 23-9
58. Madrid PB, Chopra S, Manger ID, et al. A systematic screen of FDA-approved drugs for inhibitors of biological threat agents. PLoS One 2013;8(4):e60579
59. Warren TK, Warfield KL, Wells J, et al. Antiviral activity of a small-molecule inhibitor of filovirus infection. Antimicrob Agents Chemother 2010;54(5):2152-9
60. Aman MJ, Kinch MS, Warfield K, et al. Development of a broad-spectrum antiviral with activity against Ebola virus. Antiviral Res 2009;83(3):245-51